Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The Investment Case For GlycoMimetics
https://seekingalpha.com/article/4389595-investment-case-for-glycomimetics
Funds invested in Redhill has gone up considerably with Q 3 funds holdings, will be interesting to see Q 4 stake.
https://whalewisdom.com/stock/rdhl
Ibex Investment LLC reports updated holdings of 8.67% of their portfolio is in RDHL RedHill Biopharma Ltd. ADR`s
https://whalewisdom.com/filer/lazarus-management-co-llc#tabholdings_tab_link
We are in good hands with H.C. Wainwright & Co.
Meet Our Analysts
https://hcwco.com/services/research/meet-our-analysts/#toggle-id-18-closed
Completed Transactions
https://hcwco.com/transactions/
Our Research Department consists of highly skilled professionals whose timely, insightful, and targeted research is one of the firm’s core strengths. H.C. Wainwright analysts pride themselves on their ability to identify compelling investment opportunities for our clients by discovering high-quality, undervalued companies before they are recognized by the market at large. Our analysts’ in-depth expertise and strong industry relationships enable them to remain at the forefront of the market trends impacting the companies they follow. By clearly and effectively presenting their investment theses and their expectations for both performance and risk, the firm’s research professionals help investors make sound decisions in today’s volatile markets.
AbCellera Biologics Inc CEO talks on CNBC today about the effectiveness of Covid-19 antibody treatment which Redhill is already doing basically and their stock go`s up more than $3 dollars.
GSK, Vir, Start COVID-19 Antibody Study GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) announced an agreement with the U.K.-based AGILE initiative to evaluate VIR-7832 in patients with mild-to-moderate COVID-19 in a Phase 1b/2a clinical trial their stocks run.
I for one am looking forward to what opaganib will bring to the table as we have been at this a lot longer.
Full analysis of the data, including viral and inflammatory biomarker analyses, baseline risk factors and SoC background therapy stratifications, is expected in the coming weeks. The Company will provide the data for peer review when available.
"Opaganib has a unique dual mode of action that is both anti-inflammatory and antiviral – acting on both the cause and the effects of COVID-19. Opaganib targets sphingosine kinase-2, a human cell component involved in viral replication and not the virus itself. The mounting evidence of new SARS-CoV-2 mutations emerging globally underscores the importance of this unique mechanism, which potentially minimizes the risk of viral resistance to therapy. The trends of patient improvement shown by the preliminary top-line data support the ongoing Phase 2/3 study with opaganib, which will provide a more in-depth understanding of opaganib's activity."
The efficacy of opaganib in severe COVID-19 pneumonia is being further explored in an ongoing global Phase 2/3 study and is expected to report top-line data in the first quarter of 2021. This study (NCT04467840) is being conducted across approximately 30 clinical sites in several countries and is on track to enroll up to 270 patients. The study has undergone two unblinded reviews of safety data by an independent Data and Safety Monitoring Board (DSMB), with unanimous recommendations to continue the study. An interim DSMB futility analysis will be conducted in the coming weeks, evaluating data from the first 135 subjects that have reached the primary endpoint.
The top-line results from the U.S. Phase 2 study of opaganib in patients hospitalized with COVID-19 pneumonia are preliminary and were provided to the Company by an independent third-party following an initial independent analysis and remain subject to additional review and analysis. Such review and analysis may result in findings inconsistent with the results disclosed in this release and may not be replicated in future studies.
Already listened to it thanks. Just keeping a small core position for now.
This is not new information but nice to see it in a medical journal. I believe if it were not for this Covid pandemic, they would be having some great sales with many of their commercial compounds.
March 2nd, 2021 will be Q4 2020 earnings release, so we should get some number's on sales then.
Pretty much the bottom line is Redhills Talicia FDA approved 3-in-1 combination product of omeprazole, amoxicillin, and rifabutin for the treatment of H. pylori infection in adults works with an eradication rate of 83.8%, which is excellent.
Upcoming Events & Presentations
https://ir.redhillbio.com/events
Investors should listen to this virtual conference below, also look at the upcoming presentations:
Jan 11 - 14, 2021
H.C. WAINWRIGHT BIOCONNECT 2021 CONFERENCE
Speaker: Guy Goldberg
Chief Business Officer
Link to Webcast: https://journey.ct.events/view/64ff7336-eb4d-4e5e-88fc-083e9f43312e
What a misleading title "under pressure" it`s already a done deal. Another SA buffoon piece.....
IMO, Redhill did well on this offering.....
Kala Pharmaceuticals Announces Commercial Availability of Eysuvis for the Treatment of Dry Eye Disease
https://eyewire.news/articles/kala-pharmaceuticals-announces-commercial-availability-of-eysuvis-for-the-treatment-of-dry-eye-disease/
H.C. WAINWRIGHT KEEPS THEIR BUY RATING ON KALA PHARMACEUTICALS (KALA)
https://www.markets.co/h-c-wainwright-keeps-their-buy-rating-on-kala-pharmaceuticals-kala/289474/?fbclid=IwAR2j54gkWtdQEbrB8BojgPCxhbbQrKFqKRs5RwA1gNoK6c0-nkb70brMvZs
Wedbush analyst Liana Moussatos reiterated a Buy rating on Kala Pharmaceuticals (KALA) yesterday and set a price target of $49.00. The company’s shares closed last Thursday at $7.08.
According to TipRanks.com, Moussatos is a 5-star analyst with an average return of 14.7% and a 57.1% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Catabasis Pharmaceuticals, Global Blood Therapeutics, and Eiger Biopharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Kala Pharmaceuticals with a $26.25 average price target.
Based on Kala Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $2.22 million and GAAP net loss of $27.95 million. In comparison, last year the company earned revenue of $1.45 million and had a GAAP net loss of $23.18 million.
Kala Pharmaceuticals (NASDAQ:KALA) has commercially launched EYSUVIS 0.25% for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease.
The company says that it is progressing its development of pre-clinical stage new chemical entities targeted to address front and back of the eye diseases.
Expects cash, cash equivalents and short-term investments of ~$153.5M as of December 31, 2020, including net proceeds from ATM offering during Q4, to fund its operations into at least 4Q22.
That`s what it usually means if no more recruiting, but we`ll need to wait for full completion of trials for read outs that was started in Russia 2/3 trial on July, 16th, 2020,
Remember Redhill still can give Opaganib for compassionate use and that will add to the ongoing trial studies outcomes.
Redhill Biopharma shares are trading higher after the company says six coronavirus patients were treated with the company's Opaganib under compassionate use which showed objective clinical improvement.
Hal Mintz Stocks Portfolio
They acquired 4.64% of $ATNM`s float in recent new filling today.
https://hedgefollow.com/funds/Sabby+Management
My Top SPAC Plays for 2021
https://realmoney.thestreet.com/investing/stocks/my-top-spac-play-for-2021-15530334
Get Significant Exposure to E-Commerce with Foley Trasimene Acquisition II Stock
While waiting for the Paysafe merger to close, investors can expect BFT stock to climb higher
https://investorplace.com/2021/01/get-significant-exposure-to-e-commerce-with-bft-stock/
RedHill Biopharma (NASDAQ:RDHL) announce positive safety and efficacy data from Covid-19 study
The Biotech Paradox of 2020: A Year In Review
https://lifescivc.com/2021/01/the-biotech-paradox-of-2020-a-year-in-review/
Seems like a very simple value proposition. Fits my sweet spot of being scientifically de-risked. Radiotherapy is a very real thing now in other areas, oncology definitely lends itself to it. Can hit both CD 45 and CD 33 and will be able to do both at once as well. Have shown dose response as expected. Side effects superior to alternative treatments. Safe for patients over 60. About a $100 M MC. Tiny company has this therapy in 10 of the largest transplant centers across the US which bodes well if/once approved.
Thank You for Investing in Science
https://www.nasdaq.com/articles/thank-you-for-investing-in-science-2020-12-28
Hookipa: Data Readouts Of 2021's HB-101, HB-201, And HB-201/-202 Hold Promising Upside
https://seekingalpha.com/article/4396866-hookipa-data-readouts-of-2021s-hbminus-101-hbminus-201-and-hbminus-201minus-202-hold
Stock has sold off so much the past few days on thin volume so i`ve added to my position. The stock has been touching/sitting on the 1 year 50 day SMA the past 2 days. It could go lower, but that is not because the science is bad, it has more to do with investors impatience awaiting ongoing trial data. EOY and thin volume have hit many small biotech companies the week.
Actinium Announces Successful Pre-Planned Ad Hoc Interim Analysis of Phase 3 SIERRA trial
- 100% rate of BMT and engraftment in patients receiving therapeutic dose of Iomab-B and lower rates of sepsis and sepsis related Grade ≥3 adverse events compared to patients receiving salvage therapies at 75% enrollment recently highlighted in oral presentations at ASH 2020 Annual Meeting
- Independent Data Monitoring Committee recommends SIERRA continue as planned to full enrollment of 150 patients; trial is currently over 75% enrolled
- SIERRA trial remains the only randomized Phase 3 trial to offer potentially curative bone marrow transplant as an option for patients with active relapsed or refractory AML
More here-Tables to review
https://www.prnewswire.com/news-releases/actinium-announces-successful-pre-planned-ad-hoc-interim-analysis-of-phase-3-sierra-trial-301198869.html
Have been able to free up cash and been adding here with this latest selloff. A lot of year end selling going on in biotech's so pick next year and beyond winners wisely.
From December 8th at Benzinga Global Small Cap Conference Day 1 Recap:
Actinium Pharmaceuticals Says SIERRA Trial Has Demonstrated All Patients Receiving Therapeutic Dose Of Iomab-B Have Been Able To Go On to Bone Marrow Transplant
Actinium Pharmaceuticals Says Estimates ~176K Patients/Year Diagnosed With Blood Cancers Treatable With Bone Marrow Transplant But Only 23K Transplants Performed In 2018, Says Looking To Address Access Gap With Iomab-B
Actinium Pharmaceuticals CFO Steve O'Loughlin Notes Co.'s ARCs Enable Targeted Radiotherapy Directly To Cancer Cells; Says Has Over 130 Patents That Protect Candidates Through 2037 And Beyond
Actinium Pharmaceuticals CFO Steve O'Loughlin Highlights Co. Balance Sheet; ~$48M In Cash, Which Can Fund Operations Through 2021
Actinium Pharmaceuticals CFO Steve O'Loughlin Says Co. Led By Iomab-B, Which Is In Phase 3 SIERRA Trial; Has Also Expanded Into Bone Marrow, Transplant CAR-T And Gene Therapy
Actinium Reports 67% Overall Response Rate In First Cohort In Actimab-A Venetoclax Combination Trial In Relapsed And Refractory AML At ASH 2020
12:05 ET - Investors flee Actinium Pharmaceuticals after an interim analysis of its Phase 3 study of Iomab-B for bone marrow transplant conditioning, but Maxim Group says they should be buying. Actinium terms the pre-planned analysis successful and says the study's independent data monitoring committee recommends that it continue to full enrollment. Analysts at Maxim think investors may have been expecting to see data on the primary endpoint of six-month durable complete remission or for the trial be stopped for efficacy. Maxim notes that endpoint data was only viewed by the monitoring committee, not Actinium, and that the panel's recommendation that the trial move forward to completion is overall positive, and "we would be buyers of ATNM shares on today's weakness." Actinium down 23.2% to $8.23. (colin.kellaher@wsj.com)
ATNM H.C. Wainwright keeps Buy on Actinium amid 'headline disappointment'
H.C. Wainwright analyst Joseph Pantginis reiterates a Buy rating on Actinium Pharmaceuticals with a $65 price target after the independent Data Monitoring Committee recommended that the SIERRA trial continue as planned to full enrollment of 150 patients. The analyst attributes today's stock selloff to "headline disappointment" that the study was not halted for efficacy, despite the "strong" clinical efficacy and safety profile of Iomab-B to date. However, it is important to highlight that for this relatively small study targeting 150 patients in total, the statistical hurdle was quite high for this Data Monitoring Committee look, Pantginis tells investors in a re search note. The final p-value required for success still remains 0.046, adds the analyst. Pantginis continues to project a positive outcome for SIERRA and believes that the readout could come in mid-2021. SIERRA could deliver "game-changing therapy" for active relapsed or refractory acute myeloid leukemia, says Pantginis.
10:29 EST ATNM
Actinium selloff today 'clear buying opportunity,' says JonesTrading
JonesTrading analyst Soumit Roy reiterates a Buy rating on Actinium Pharmaceuticals with a $40 price target after the company announced that the Data Monitoring Committee recommended for the continuation of the Phase 3 SIERRA trial in active relapsed or refractory acute myeloid leukemia to completion. Actinium did not receive the unblinded primary and secondary endpoint efficacy data from SIERRA, Roy tells investors in a research note. Regarding today's stock weakness, the analyst says that given the "robust" efficacy data from SIERRA at 75% completion, there was expectations among investors that SIERRA could get terminated earlier before full completion. However , Roy points out that the Data Monitoring Committee's decision was based on less than two-thirds of the total trial size, so the trigger for early stoppage was higher than the two-times threshold for six month disease control rate at 100% enrollment. Most of the pressure on the stock today is due to selloff from retail investors and is a "clear buying opportunity," Roy says. Actinium shares in morning trading is down 25% to $8.04.
Institutional Ownership and Shareholders
Redhill Biopharma Ltd (US:RDHL) has 73 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 7,891,806 shares. Largest shareholders include Disciplined Growth Investors Inc /mn, Ibex Investors LLC, Migdal Insurance & Financial Holdings Ltd., Creative Planning, Gagnon Securities Llc, IZRL - ARK Israel Innovative Technology ETF, Susquehanna International Group, Llp, Schonfeld Strategic Advisors LLC, Wells Fargo & Company/mn, and Sculptor Capital LP.
Redhill Biopharma Ltd (US:RDHL) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds (or held) more than 5% of the company and intends (or intended) to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%
https://fintel.io/so/us/rdhl
Redhill Biopharma Ltd. - American Depositary Shares (RDHL)
The 5 analysts offering 12-month price forecasts for Redhill Biopharma Ltd have a median target of 23.00, with a high estimate of 27.00 and a low estimate of 12.00. The median estimate represents a +146.78% increase from the last price of 9.32. The current consensus among 5 polled investment analysts is to buy stock in Redhill Biopharma Ltd. This rating has held steady since September, when it was unchanged from a buy rating.
Analyst Ratings Link
Been a long time just going nowhere and it`s time to move back to the old highs.
5 year chart link...
insert-text-here
Easily......
BFT-Paysafe and Apple are working together...
https://www.paysafe.com/gb-en/apple-pay/
My take on RDHL updated-Target $25.00
RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on gastrointestinal and infectious diseases. They have three FDA approved gastrointestinal drugs: Movantik for opioid-induced constipation in adults, Talicia for Helicobacter pylori (H. pylori) infection in adults, and Aemcolo for travellers’ diarrhoea in adults.
RedHill has clinical late stage development pipeline which includes two Phase 2/3 programs in COVID-19 (opaganib and RHB-107), RHB-204 in a Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) disease, RHB-104 which successfully completed a first Phase 3 study for Crohn's disease, and RHB-102 which completed a Phase 3 study for acute gastroenteritis and gastritis and a Phase 2 study for IBS-D. IBS-D or "Irritable bowel syndrome with diarrhea" would be an extremely large unmet market. IBS-D is an untreated disability with many people suffering from it. Their commercial medications are held back due to Covid, yet company is involved in finding some remedy that may help eradicate or ease Covid symptoms.
In brief
RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes three FDA-approved gastrointestinal drugs: Movantik® for opioid-induced constipation in adults, Talicia® for Helicobacter pylori (H. pylori) infection in adults, and Aemcolo® for travellers’ diarrhoea in adults. RedHill also has an extensive clinical late-stage development pipeline which includes two Phase 2/3 programs in COVID-19 (opaganib and RHB-107), RHB-204 in a Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) disease, RHB-104 which successfully completed a first Phase 3 study for Crohn's disease, and RHB-102 which completed a Phase 3 study for acute gastroenteritis and gastritis and a Phase 2 study for IBS-D.
I`m looking forward to the successful trial with their IBS-D study as this is a highly undertreated disability with many people suffering from it and only over the counter medication available.
https://www.proactiveinvestors.com/NASDAQ:RDHL/RedHill-Biopharma/
Next earnings release-
MAR 09 2021
Q4 2020 Earnings Release
EPS estimate consensus $0.002
Estimate range -$0.02 to $0.03
Previous year's Q4 actual -$0.10